GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Cyclically Adjusted PB Ratio

Aravive (Aravive) Cyclically Adjusted PB Ratio : 0.00 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Aravive's current share price is $0.0401. Aravive's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $18.83. Aravive's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Aravive's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Aravive's highest Cyclically Adjusted PB Ratio was 0.16. The lowest was 0.01. And the median was 0.08.

ARAV's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aravive's adjusted book value per share data for the three months ended in Sep. 2023 was $0.023. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $18.83 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aravive Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Aravive's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Cyclically Adjusted PB Ratio Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.07

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.10 0.07 0.01

Competitive Comparison of Aravive's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Aravive's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aravive's Cyclically Adjusted PB Ratio falls into.



Aravive Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aravive's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0401/18.83
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aravive's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Aravive's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.023/129.8595*129.8595
=0.023

Current CPI (Sep. 2023) = 129.8595.

Aravive Quarterly Data

Book Value per Share CPI Adj_Book
201312 -12.197 98.326 -16.109
201403 49.869 99.695 64.958
201406 47.978 100.560 61.957
201409 44.943 100.428 58.114
201412 41.419 99.070 54.292
201503 46.669 99.621 60.835
201506 43.418 100.684 55.999
201509 39.681 100.392 51.329
201512 35.996 99.792 46.841
201603 31.548 100.470 40.776
201606 27.570 101.688 35.208
201609 22.493 101.861 28.676
201612 26.013 101.863 33.163
201703 21.586 102.862 27.251
201706 16.053 103.349 20.171
201709 8.250 104.136 10.288
201712 13.816 104.011 17.249
201803 12.747 105.290 15.722
201806 11.413 106.317 13.940
201809 10.549 106.507 12.862
201812 5.321 105.998 6.519
201903 4.874 107.251 5.901
201906 4.685 108.070 5.630
201909 4.212 108.329 5.049
201912 4.603 108.420 5.513
202003 3.929 108.902 4.685
202006 3.716 108.767 4.437
202009 3.069 109.815 3.629
202012 2.916 109.897 3.446
202103 3.382 111.754 3.930
202106 3.092 114.631 3.503
202109 2.599 115.734 2.916
202112 2.007 117.630 2.216
202203 1.614 121.301 1.728
202206 0.985 125.017 1.023
202209 0.493 125.227 0.511
202212 0.178 125.222 0.185
202303 -0.645 127.348 -0.658
202306 -0.331 128.729 -0.334
202309 0.023 129.860 0.023

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aravive  (NAS:ARAV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aravive Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Aravive's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (Aravive) Business Description

Industry
Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines

From GuruFocus

Aravive Appoints Rudy Howard as Chief Financial Officer

By PurpleRose PurpleRose 07-13-2022

Aravive To Participate in the Jefferies Global Healthcare Conference

By sperokesalga sperokesalga 06-05-2023